Fusion Pharmaceuticals
combination of sub therapeutic single agent doses resulted in enhanced anti tumor activity sip to low dose single | Fusion Pharmaceuticals
Deck Type
IPO
Deck date
June 2020
Slide
34 of 49
Related slides by other companies
Investor Day
November 2022
Other recent decks by Fusion Pharmaceuticals
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
August 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io